A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries, including the Nordic countries for more than 20 years. The company serves more than 160 countries with the support of a large network of distributors.
bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
The bioMérieux Nordic office, which covers Denmark, Finland, Norway and Sweden, is now establishing itself at GoCo Health Innovation City in January 2024.
- We are incredibly happy to welcome bioMérieux Nordic to GoCo Health Innovation City. Their physical presence in the area as well as their contribution to the community will be important and valuable for the health ecosystem, says Marie Uddenmyr, Director of Corporate Relations at GoCo Health Innovation City.
bioMérieux Nordic is a great addition in the GoCo community. By bringing people together, a culture of collaboration and innovation can be fostered to accelerate health innovation. The existing ecosystem of academia, public sector and industry operating at GoCo works closely together, both geographically and conceptually, towards life science innovations for a healthier future.
- At bioMérieux, innovation is part of our DNA. We are very excited to establish our new Nordic Headquarter in January 2024 at GoCo Health Innovation City. We believe this will help us create new partnerships within an innovative healthcare ecosystem to advance diagnostics, said Denis Monnaie, Vice President, Clinical Operations, Benelux Nordic at bioMérieux.
Find more information about bioMérieux on their website www.biomerieux.com.
Photo credit @bioMérieux - Florent Dubray.
We use cookies to ensure that we give you the best experience on our website. By continuing to browse the site you are agreeing to our use of cookies. Read more about our data and privacy policy here.
OK